EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical significance of FLC tests in patients without other evidence of hematologic disorder

Dor Shpitzer, Yael C Cohen, Chava Perry, Guy Melamed, Hillel Alapi, Anat Reiner-Benaim, Irit Avivi

Clinical and Experimental Medicine · 2024

DOI: 10.1007/s10238-024-01471-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Dor Shpitzer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Biostatistics and Community Health Sciences, Faculty of Health Sciences, School of Public Health, Ben Gurion University o…. Hauptthemen laut MEDLINE: Immunoglobulin Light Chains. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical significance of an abnormal free light chain (FLC) test, performed due to unspecific complains in the absence of a known plasma cell dyscrasia (PCD) or lymphoproliferative disease (LPD), is not fully elucidated. We investigated the importance of an abnormal FLC ratio (FLC-R) in this setting. Patients registered in the Maccabi Healthcare Services database, tested for FLC during 2007-2023 without previously documented PCD/LPD or increased total protein (TP) level, were reviewed. Demographics, co-morbidities, and laboratory tests were recorded. FLC-R was defined as normal (0.26-1.65) or slightly (slAb 0.1-0.26/1.65-4), moderately (mAbn 0.1-0.05/4-8) and significantly abnormal (sigAb- 8). Factors associated with PCD/LPD and overall survival were identified. In total, 8,661 patients, 2,215 (25.6%) with abnormal FLC-R [2,090 (24.1%)-slAb, 65 (0.75%)-mAbn and 60 (0.7%)-sigAb], were analyzed. Almost none had anemia nor acute renal failure. 14% had concomitant increased immunoglobulins. Within a median follow-up of 52 months, 943 were diagnosed with PCD (816-MGUS, 127-MM/Amyloidosis/plasmacytoma) and 48 with LPD. Median time to PCD and LPD were 19 and 28 months. Multivariate analysis found slAb (HR = 1.8, CI95%:1.53-2.12, p < 0.001), mAbn (HR = 6.3, CI95%:4.16-9.53, p < 0.001), and sigAb FLC (HR = 10.4, CI95%:7.0-15.35, p < 0.001), to be associated with PCD/LPD diagnosis. Decreased IgG, increased IgA, and concomitant comorbidities predicted PCD, whereas increased IgM predicted LPD. Older age, male gender, anemia, decreased albumin, increased IgG and concomitant comorbidities, predicted shorter survival. Our large study emphasizes the independent clinical significance of abnormal FLC-R as a predictor of PCD/LPD diagnosis even in patients with normal TP level, promoting early detection of PCD/LPD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light ChainsHumansMaleFemaleMiddle AgedAgedAged, 80 and overAdultParaproteinemiasRetrospective StudiesSurvival AnalysisLymphoproliferative DisordersHematologic DiseasesClinical Relevance

Stichwörter der Autor:innen

FLCMGUSMultiple MyelomaPCD

Substanzen

Immunoglobulin Light Chains

Autor:innen und Institutionen

  • Department of Epidemiology, Biostatistics and Community Health Sciences, Faculty of Health Sciences, School of Public Health, Ben Gurion University of the Negev, Beer Sheva, Israel. shpitzerd@gmail.com.
  • Tel -Aviv Sourasky (Ichilov) Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Kahn Sagol Maccabi Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel.
  • Department of Epidemiology, Biostatistics and Community Health Sciences, Faculty of Health Sciences, School of Public Health, Ben Gurion University of the Negev, Beer Sheva, Israel.

Zitieren

APA

Shpitzer, D., Cohen, Y. C., Perry, C., Melamed, G., Alapi, H., Reiner-Benaim, A., & Avivi, I. (2024). Clinical significance of FLC tests in patients without other evidence of hematologic disorder. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01471-4

Vancouver

Shpitzer D, Cohen YC, Perry C, Melamed G, Alapi H, Reiner-Benaim A, et al. Clinical significance of FLC tests in patients without other evidence of hematologic disorder. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01471-4

BibTeX
@article{Shpitzer2024,
  author = {Shpitzer, Dor and Cohen, Yael C and Perry, Chava and Melamed, Guy and Alapi, Hillel and Reiner-Benaim, Anat and Avivi, Irit},
  title = {Clinical significance of FLC tests in patients without other evidence of hematologic disorder},
  journal = {Clinical and Experimental Medicine},
  year = {2024},
  doi = {10.1007/s10238-024-01471-4}
}
Kostenlos starten →